• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    8/10/22 4:17:03 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVFM alert in real time by email
    SC 13G/A 1 d363979dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    EVOFEM BIOSCIENCES, INC.

    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.0001 PER SHARE

    (Title of Class of Securities)

    30048L104

    (CUSIP Number)

    AUGUST 9, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d–1(b)

     

      ☒

    Rule 13d–1(c)

     

      ☐

    Rule 13d–1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 30048L104

     

      1    

      Name of Reporting Person

     

      Todd Stewart Cox

      2  

      Check the Appropriate Box if a Member of a Group

     

      (A):  ☐        (B):  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    with

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      0

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      ☐

    11  

      Percent of Class Represented by Amount in Row (9)

     

      0% (1)(2)

    12  

      Type of Reporting Person

     

      IN

     

    (1)

    Based on 82,449,214 shares of common stock, par value $0.0001 per share, of Evofem Biosciences, Inc., a Delaware corporation (the “Issuer”), issued and outstanding as of August 3, 2022 (see Exhibit 99.1 to Issuer’s Current Report on Form 8-K filed on August 4, 2022).

    (2)

    Includes 0 shares of common stock held in a joint account with Mr. Cox’s spouse, Kathy Overstreet Cox.


    CUSIP No. 30048L104

     

      1    

      Name of Reporting Person

     

      Kathy Overstreet Cox

      2  

      Check the Appropriate Box if a Member of a Group

     

      (A):  ☐        (B):  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    with

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      0

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      ☐

    11  

      Percent of Class Represented by Amount in Row (9)

     

      0% (1)(2)

    12  

      Type of Reporting Person

     

      IN

     

    (1)

    Based on 82,449,214 shares of common stock, par value $0.0001 per share, of the Issuer issued and outstanding as of August 3, 2022 (see Exhibit 99.1 to Issuer’s Current Report on Form 8-K filed on August 4, 2022).

    (2)

    Includes 0 shares of common stock held in a joint account with Mrs. Cox’s spouse, Todd Stewart Cox.


    CUSIP No. 30048L104

     

    Item 1(a).

    Name of issuer:

    Evofem Biosciences, Inc.

     

    Item 1(b).

    Address of issuer’s principal executive offices:

    12400 High Bluff Drive, Suite 600

    San Diego, CA 92130

     

    Item 2(a).

    Names of persons filing:

    Todd Stewart Cox

    Kathy Overstreet Cox

     

    Item 2(b).

    Address or principal business office or, if none, residence of each Reporting Person:

    320 Creek Crossing Drive

    Georgetown, TX 78628

     

    Item 2(c).

    Citizenship:

    Todd Stewart Cox: United States

    Kathy Overstreet Cox: United States

     

    Item 2(d).

    Title of class of securities:

    Common stock, par value $0.0001 per share, of Evofem Biosciences, Inc.

     

    Item 2(e).

    CUSIP number:

    30048L104

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership:

    The information regarding ownership set forth in Items 5-9 and 11 of the attached cover pages is hereby incorporated herein by reference.

     

    Item 5.

    Ownership of five percent or less of a class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒.

     

    Item 6.

    Ownership of more than five percent on behalf of another person:

    Not applicable.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person:

    Not applicable.


    CUSIP No. 30048L104

     

    Item 8.

    Identification and classification of members of the group:

    Not applicable.

     

    Item 9.

    Notice of dissolution of group:

    Not applicable.

     

    Item 10.

    Certifications:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: August 10, 2022

     

    Todd Stewart Cox
    By:   /s/ Todd Stewart Cox
      Name: Todd Stewart Cox
    Kathy Overstreet Cox
    By:   /s/ Kathy Overstreet Cox
      Name: Kathy Overstreet Cox

     

    Get the next $EVFM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVFM

    DatePrice TargetRatingAnalyst
    3/4/2022$0.50 → $0.53Underweight
    Morgan Stanley
    11/16/2021$2.50 → $2.00Buy
    HC Wainwright & Co.
    10/21/2021$4.00 → $2.50Buy
    HC Wainwright & Co.
    10/14/2021$0.80Equal-Weight → Underweight
    Morgan Stanley
    8/12/2021$3.00 → $1.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $EVFM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

      SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO. "First quarter net sales were soft, as expected, due to the high level of PHEXXI stocking orders in the fourth qua

      5/15/25 7:59:00 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

      Event Begins Today at 11:30 a.m. ET Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt's CIO Dr. Shahrokh Shabahang, and Adimune's Co-CEO Dr. Friedrich Kapp, will join today's Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune. Event Details: Title: Aditxt Weekly Update Date: Friday, May 2, 2025 Time: 11:30 a.m. ET Location: Virtual (Zoom) Registration: Click here to register About Adimune Adimune is a pre-clinical stage biopharmaceutical company pioneering a new class of immune modulation therapie

      5/2/25 9:00:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

      4/17/25 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Evofem Biosciences Inc.

      10-Q - Evofem Biosciences, Inc. (0001618835) (Filer)

      5/15/25 8:10:35 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evofem Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

      5/15/25 8:05:12 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

      5/8/25 4:05:12 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    Financials

    Live finance-specific insights

    See more
    • Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

      SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO. "First quarter net sales were soft, as expected, due to the high level of PHEXXI stocking orders in the fourth qua

      5/15/25 7:59:00 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician

      4/15/25 8:00:00 AM ET
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evofem Reports Fourth Consecutive Year of Net Sales Growth

      -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

      3/24/25 8:30:00 AM ET
      $ADTX
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $EVFM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley reiterated coverage on Evofem Biosciences with a new price target

      Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Underweight and set a new price target of $0.53 from $0.50 previously

      3/4/22 8:06:41 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Evofem Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.00 from $2.50 previously

      11/16/21 9:42:11 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Evofem Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.50 from $4.00 previously

      10/21/21 6:49:27 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

      4/17/25 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

      Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

      10/29/24 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

      Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as

      8/26/24 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zhang Yan sold $4 worth of shares (104 units at $0.04), closing all direct ownership in the company (SEC Form 4)

      4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

      1/12/24 5:13:24 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamdar Kim P. sold $6 worth of shares (10 units at $0.62), closing all direct ownership in the company (SEC Form 4)

      4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

      12/22/23 4:05:30 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 5 filed by File Justin J.

      5 - Evofem Biosciences, Inc. (0001618835) (Issuer)

      5/8/23 4:05:19 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

      SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

      2/14/24 2:14:48 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

      SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

      2/14/23 11:24:47 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

      SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

      8/10/22 4:17:03 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care